Hubrecht Institute for Developmental Biology and Stem Cell Research, Cancer Genomics Center, Royal Netherlands Academy of Sciences and University Medical Center Utrecht, Uppsalalaan 8, Utrecht, The Netherlands.
Pharmacogenomics J. 2011 Oct;11(5):326-36. doi: 10.1038/tpj.2010.44. Epub 2010 Jun 8.
G-protein-coupled receptors (GPCRs) constitute a large family of cell surface receptors that are involved in a wide range of physiological and pathological processes, and are targets for many therapeutic interventions. However, genetic models in the rat, one of the most widely used model organisms in physiological and pharmacological research, are largely lacking. Here, we applied N-ethyl-N-nitrosourea (ENU)-driven target-selected mutagenesis to generate an in vivo GPCR mutant collection in the rat. A pre-selected panel of 250 human GPCR homologs was screened for mutations in 813 rats, resulting in the identification of 131 non-synonymous mutations. From these, seven novel potential rat gene knockouts were established as well as 45 lines carrying missense mutations in various genes associated with or involved in human diseases. We provide extensive in silico modeling results of the missense mutations and show experimental data, suggesting loss-of-function phenotypes for several models, including Mc4r and Lpar1. Taken together, the approach used resulted not only in a set of novel gene knockouts, but also in allelic series of more subtle amino acid variants, similar as commonly observed in human disease. The mutants presented here may greatly benefit studies to understand specific GPCR function and support the development of novel therapeutic strategies.
G 蛋白偶联受体 (GPCRs) 是细胞表面受体大家族的一员,广泛参与各种生理和病理过程,也是许多治疗干预的靶点。然而,在生理和药理学研究中广泛使用的模式生物大鼠中,遗传模型却在很大程度上缺乏。在这里,我们应用 N-乙基-N-亚硝脲 (ENU) 驱动的靶向选择诱变,在大鼠中生成了一个体内 GPCR 突变体集合。对 813 只大鼠进行了预筛选的 250 个人类 GPCR 同源物面板的突变筛选,鉴定出 131 个非同义突变。其中,确定了七个新的潜在大鼠基因敲除体,以及 45 条携带与人类疾病相关或涉及的各种基因中的错义突变的品系。我们提供了大量错义突变的计算建模结果,并展示了实验数据,表明了几种模型(包括 Mc4r 和 Lpar1)存在功能丧失表型。总之,所采用的方法不仅产生了一组新的基因敲除体,而且还产生了一系列更微妙的氨基酸变异等位基因,与人类疾病中常见的情况类似。本文介绍的突变体可能会极大地促进对特定 GPCR 功能的研究,并支持新型治疗策略的开发。